Literature DB >> 12052002

Analysis of solvent central nervous system toxicity and ethanol interactions using a human population physiologically based kinetic and dynamic model.

A J MacDonald1, A Rostami-Hodjegan, G T Tucker, D A Linkens.   

Abstract

The effect of acute ethanol-mediated inhibition of m-xylene metabolism on central nervous system (CNS) depression in the human worker population was investigated using physiologically based pharmacokinetic (PBPK) models and probabilistic random (Monte Carlo) sampling. PBPK models of inhaled m-xylene and orally ingested ethanol were developed and combined by a competitive enzyme (CYP2E1) inhibition model. Human interindividual variability was modeled by combining estimated statistical distributions of model parameters with the deterministic PBPK models and multiple random or Monte Carlo simulations. A simple threshold pharmacodynamic model was obtained by simulating m-xylene kinetics in human studies where CNS effects were observed and assigning the peak venous blood m-xylene concentration (C(V,max)) as the dose surrogate of toxicity. Probabilistic estimates of an individual experiencing CNS disturbances given exposure to the current UK occupational exposure standard (100 ppm time-weighted average over 8 h), with and without ethanol ingestion, were obtained. The probability of experiencing CNS effects given this scenario increases markedly and nonlinearly with ethanol dose. As CYP2E1-mediated metabolism of other occupationally relevant organic compounds may be inhibited by ethanol, simulation studies of this type should have an increasingly significant role in the chemical toxicity risk assessment. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052002     DOI: 10.1006/rtph.2001.1507

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  5 in total

1.  Using a pharmacokinetic model to relate an individual's susceptibility to alcohol dependence to genotypes.

Authors:  Laura F Mustavich; Perry Miller; Kenneth K Kidd; Hongyu Zhao
Journal:  Hum Hered       Date:  2010-08-12       Impact factor: 0.444

2.  Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.

Authors:  Stefan Willmann; Karsten Höhn; Andrea Edginton; Michael Sevestre; Juri Solodenko; Wolfgang Weiss; Jörg Lippert; Walter Schmitt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-03-13       Impact factor: 2.410

3.  A Workflow for Global Sensitivity Analysis of PBPK Models.

Authors:  Kevin McNally; Richard Cotton; George D Loizou
Journal:  Front Pharmacol       Date:  2011-06-23       Impact factor: 5.810

4.  Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation.

Authors:  Kevin McNally; Richard Cotton; John Cocker; Kate Jones; Mike Bartels; David Rick; Paul Price; George Loizou
Journal:  J Toxicol       Date:  2012-04-08

5.  The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans.

Authors:  George D Loizou; Kevin McNally; Kate Jones; John Cocker
Journal:  Front Pharmacol       Date:  2015-06-30       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.